|
|
News Breaks | | | | January 31, 2013 | | 07:06 EDT |  | DYAX, NVLS | Dyax and Novellus partner to commercialize Kalbitor in Latin America
Dyax (DYAX) and Novellus (NVLS) announced a strategic partnership for the development and commercialization of Kalbitor (ecallantide) for the treatment of hereditary angioedema and other angioedema indications in select regions in Latin America, including Argentina, Brazil, Chile, Colombia, Mexico and Venezuela. Kalbitor is marketed in the U.S. for the treatment of acute attacks of HAE in patients 16 years of age and older. Dyax will receive an upfront payment and is eligible to receive future sales milestones. Dyax is also eligible to receive royalties on net product sales. Novellus is solely responsible for all costs associated with necessary development, regulatory activities, and the commercialization of Kalbitor in the covered territories. | |
|
News For DYAX;NVLS From The Last 14 Days Check below for free stories on DYAX;NVLS the last two weeks. |
|
|
| May 13, 2013 | | 07:16 EDT |  | DYAX | Dyax raises $30M in a registered direct offering
 Subscribe for More Information | |
|
|
|
|
|
|
